Toxoff®

Solution For Intramuscular

MEDICATION GUIDE
TOXOFF® (Ipidacrine / NK-247)

WARNING: READ CAREFULLY **SEE FULL MEDICATION GUIDE FOR COMPLETE BOXED WARNING.**

About the medicine
Toxoff is the trade name of the drug. Ipidacrine is the generic name of the drug. For subcutaneous use in the muscle. It is a colorless, transparent liquid. There is one ampoule in the box.

Ingredient
1 ml ampoule contains 15 mg Ipidacrine. **Excipients:** Hydrochloride acid solution (pH stabilizer), water for injection, colourless liquid.

Pharmacological Properties
Ipidacrine has a direct stimulating effect. The logical effect of ipidacrine, the best strip from a pharmacological point of view, is based on a combination of treatment methods. **Two mechanisms of action:** Blockade of potassium channels in the neuronal area. Reversible inhibition of cholinesterase in synapses. Ipidacrine does not increase the effect on smooth muscle. It applies not only to acetylcholine but also to adrenaline, tamine and oxytocin.

Ipidacrine has pharmacological properties:
- It improves the transmission of impulses to the nerves, stimulating them.
- Increases the contractility of smooth muscle organs.
- Inhibits progressive development for too long
- It does not affect the disorders that have teratogenic, embryotoxic, mutagenic and genetic and immunotoxic effects (endocrine system).

Pharmacokinetics
When administered subcutaneously or intramuscularly, the drug is rapidly absorbed after administration. The maximum concentration in the blood is reached 25-30 minutes after injection. The half-life of distribution is 40 minutes, metabolized in the liver. The drug is excreted by the kidneys and also non-renally (via the gastrointestinal tract). When administered parenterally, the half-life of ipidacrine is 2-3 hours. Excretion of ipidacrine by the kidneys is mainly by tubular secretion and only 1/3 of the drug is excreted by glomerular filtration. When administered parenterally, 34.8% of the drug dose is excreted unchanged in the urine.

Indications for use
Peripheral nervous system disorders: mono- and often increased polyneuropathy polyradiculopathy, myasthenia.**Uncommon:** allergic myasthenic syndrome of various etiologies. Hypersensitivity to any component of the drug, epilepsy, perkinesia, angina pectoris and extrapyramidal disorders with severe bradycardia.

Caution should be exercised in the following situations
Gastric ulcer and duodenal ulcer, thyrotoxicosis, diseases of the cardiovascular system. During pregnancy, the drug increases the tone of the uterus.

Directions for use and dosage
It is used subcutaneously or intramuscularly. Doses and duration of treatment are determined individually depending on the condition.**Peripheral nervous system diseases:** Mono- and polyneuropathy of various origins: 15 mg 1-2 times a day subcutaneously and intramuscularly for 15 days (30 days in severe cases). The general duration of treatment is 12 months. Most likely, the treatment can be repeated several times at intervals.

Classification of reactions according to their frequency of development:
Very common(>1/10),
Common(>1/100),
Uncommon(>1/1000 to <1/100),
Very rare(<1/10,000).
Common: palpitations, chest and mediastinal disorders. Uncommon: vomiting (in case of high dose) Rare: vomiting, epigastric pain.

Skin and subcutaneous tissue disorders
Common: Increased sweating
Uncommon: Allergic skin reactions (itching, rash) (when taken in high doses)

Musculoskeletal and tissue disorders
Uncommon: muscle cramps (when using high doses)General disorders and reactions during administration:Uncommon: weakness (when using high doses) Reduce if side effects occur. Take the dose for a short time (1-2 days) or stop. **Overdose:** In case of severe overdose, 'Cholery crisis' may develop. Symptoms: loss of appetite, spasm, lacrimation, increased sweating, constriction of the pupils, spontaneous defecation and urination, vomiting, decreased blood pressure, restlessness, anxiety, coma, drowsiness and general weakness. Symptoms are poorly visible. **Treatment:** symptomatic treatment is used.

Interaction with other drugs
Toxoff increases the sedative effect in combination with drugs that depress the central nervous system. Its effect and side effects increase when used together with other cholinesterase inhibitors and cholinomimetic drugs. In patients with myasthenia gravis, the risk of developing cholinergic crisis increases if Toxoff is used simultaneously with other cholinergic drugs. If blockers were used before starting Toxoff treatment, the risk of developing bradycardia increases. Alcohol increases the side effects of the drug.

Special instructions
During the treatment process, you should refrain from driving vehicles. You should refrain from driving and engaging in potentially hazardous activities that require increased concentration and speed of psychomotor reactions.

Storage conditions
Store in a place protected from light at a temperature not exceeding 25°C. Do not use after the stated expiration date.

There is 1 ampoule in 1 blister pack. The instructions for use are in the box. Read the instructions for use carefully before starting use.

РМфарма

To report **SUSPECTED ADVERSE REACTIONS** or product complaints, contact RM Pharma ZAO.

Manufactured By: RM Pharma ZAO Presnenskaya Naberezhnaya Tower, Moscow, 123317 **Russian Federation**
For more information, visit the website **www.rm-pharma.com**
Revised 10/2023

This medication guide has been approved by the Ministry of Health of Russian Federation.